Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 12 - 11 crawled time : 20:20 save search
Karyopharm Announces Presentation of Updated Phase 2 Selinexor Data in Patients with Myelofibrosis at the American Society of Hematology 2021 Annual Meeting and Exposition
Published: 2021-12-11 (Crawled : 20:20) - prnewswire.com
KPTI | $1.155 410K
|
Health Technology
| Email alert
Add to watchlist
ema phase 2 fibrosis presentation
Janssen Presents Updated Results Evaluating First-in-Class Talquetamab (GPRC5DxCD3 Bispecific Antibody) in Heavily Pretreated Patients with Multiple Myeloma
Published: 2021-12-11 (Crawled : 20:20) - prnewswire.com
JNJ | $144.56 -2.05% 4.3M
|
Health Technology
| Email alert
Add to watchlist
GNMSF | $282.004 210
|
Health Technology
| Email alert
Add to watchlist
AMGN | $264.99 -0.2% 410K
|
Health Technology
| Email alert
Add to watchlist
GMAB | $29.335 -0.59% 86K
|
Health Technology
| Email alert
Add to watchlist
results antibody
New REGN5458 (BCMAxCD3) Phase 1 Data Show 75% Response Rate at Highest Dose Levels Studied in Patients with Heavily Pretreated Multiple Myeloma
Published: 2021-12-11 (Crawled : 20:20) - prnewswire.com
TEVJF | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
REGN | $895.57 -0.33% 180K
|
Health Technology
| Email alert
Add to watchlist
SNYNF | $92.966 630
|
Health Technology
| Email alert
Add to watchlist
SNY | $46.2 0.59% 210K
|
Health Technology
| Email alert
Add to watchlist
regn5458 phase 1
Syndax Pharmaceuticals Announces Updated Positive Data Demonstrating Broad Activity and Tolerability of Axatilimab in Patients with Chronic Graft-Versus-Host Disease
Published: 2021-12-11 (Crawled : 20:20) - prnewswire.com
SNDX | $21.61 -0.51% 47K
|
Health Technology
| Email alert
Add to watchlist
disease positive
Novartis Kymriah® demonstrates strong responses in high-risk patients with relapsed or refractory follicular lymphoma in extended study follow-up
Published: 2021-12-11 (Crawled : 20:20) - globenewswire.com
NVSEF | $93.6375 82K
|
Health Technology
| Email alert
Add to watchlist
NVS | $93.29 -1.19% 530K
|
Health Technology
| Email alert
Add to watchlist
kymriah novartis risk response
IGM Biosciences Presents Clinical Data from IGM-2323 in Patients with Advanced B Cell Malignancies at 2021 American Society of Hematology Annual Meeting
Published: 2021-12-11 (Crawled : 20:20) - globenewswire.com
IGMS | $9.39 -0.21% 25K
|
Health Technology
| Email alert
Add to watchlist
igm-2323 ema bioscience t-cell
Gainers vs Losers
| 50% | 50% |
Top 10 Gainers
TPET | $0.503 117.66% 21M
|
n/a
WISA 4 | $3.22 84.0% 56M
|
Electronic Technology
SXTC | $2.56 82.86% 11M
|
Health Technology
PRSO | $1.99 56.69% 52M
|
Manufacturing
PALI | $6.5 56.25% 22M
|
Manufacturing
JAGX | $0.1767 48.74% 430M
|
Health Technology
DYNT | $0.5255 41.87% 18M
|
Health Technology
MCBC | $13.795 38.92% 820K
|
Finance
BTTR | $6.86 34.51% 5.2M
|
Manufacturing
SNGX | $0.51 32.09% 6.3M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.